NASDAQ: KPRX
Kiora Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for KPRX

Based on 1 analyst offering 12 month price targets for Kiora Pharmaceuticals Inc

Min Forecast
$10.00+269%
Avg Forecast
$10.00+269%
Max Forecast
$10.00+269%

Should I buy or sell KPRX stock?

Based on 1 analyst offering ratings for Kiora Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KPRX stock forecasts and price targets.

KPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-02

1 of 1

Forecast return on equity

Is KPRX forecast to generate an efficient return?

Company
N/A
Industry
50.63%
Market
-24.76%

Forecast return on assets

Is KPRX forecast to generate an efficient return on assets?

Company
N/A
Industry
14.75%

KPRX earnings per share forecast

What is KPRX's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$2.45
Avg 2 year Forecast
-$2.28

KPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KPRX$2.71$10.00+269.00%Buy
BCDA$1.45$25.00+1,624.14%Buy
HCWB$3.99$35.00+777.19%Strong Buy
ADXN$10.95N/AN/A
ENTO$4.96N/AN/A

Kiora Pharmaceuticals Stock Forecast FAQ

Is Kiora Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: KPRX) stock is to Buy KPRX stock.

Out of 1 analyst, 0 (0%) are recommending KPRX as a Strong Buy, 1 (100%) are recommending KPRX as a Buy, 0 (0%) are recommending KPRX as a Hold, 0 (0%) are recommending KPRX as a Sell, and 0 (0%) are recommending KPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Kiora Pharmaceuticals stock.

What is KPRX's earnings growth forecast for 2025-2026?

(NASDAQ: KPRX) Kiora Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.87%.

Kiora Pharmaceuticals's earnings in 2025 is -$12,051,454.On average, 1 Wall Street analyst forecast KPRX's earnings for 2025 to be -$7,457,450, with the lowest KPRX earnings forecast at -$7,457,450, and the highest KPRX earnings forecast at -$7,457,450.

In 2026, KPRX is forecast to generate -$6,939,994 in earnings, with the lowest earnings forecast at -$6,939,994 and the highest earnings forecast at -$6,939,994.

What is KPRX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: KPRX) forecast ROE is N/A, which is considered weak.

What is KPRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KPRX price target, the average KPRX price target is $10.00, with the highest KPRX stock price forecast at $10.00 and the lowest KPRX stock price forecast at $10.00.

The Wall Street analyst predicted that Kiora Pharmaceuticals's share price could reach $10.00 by Sep 2, 2026. The average Kiora Pharmaceuticals stock price prediction forecasts a potential upside of 269% from the current KPRX share price of $2.71.

What is KPRX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: KPRX) Kiora Pharmaceuticals's current Earnings Per Share (EPS) is -$3.01. On average, analysts forecast that KPRX's EPS will be -$2.45 for 2025, with the lowest EPS forecast at -$2.45, and the highest EPS forecast at -$2.45. In 2026, KPRX's EPS is forecast to hit -$2.28 (min: -$2.28, max: -$2.28).

What is KPRX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: KPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 14.75%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.